首页 > 最新文献

Nutrition Clinique et Metabolisme最新文献

英文 中文
L’apport alimentaire en micronutriments dans le trouble du spectre de l’autisme chez des enfants de l’ouest Algérien 阿尔及利亚西部儿童自闭症谱系障碍的膳食微量营养素摄入量
IF 0.6 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-03-01 DOI: 10.1016/j.nupar.2023.09.005
Nawel Amraoui , Nouria Dennouni-Medjati , Majda Dali-Sahi , Yahia Harek , Baya Guermouche , Cherifa Benosman

Autism Spectrum Disorders (ASD) can affect the nutritional status of children. This study aimed to assess the daily dietary intakes (DDI) of micronutrients, as well as the frequency of consumption (FC) of different food groups, in children with ASD and compare them to those with typical development (TD). It will also determine to what extent these intakes comply with the Recommanded Dietary Allowances (RDA). The study included 52 children, 26 with ASD and 26 with TD. DDI and FC were gathered using a 7-day food diary. Among the DDI of micronutrient, only Vit B12 showed a significant difference between cases and controls, but the DDI was higher than the recommendations in both groups studied. All the children of our study sample had DDI lower than the RDA, in iron, calcium, vitamins E and K1. However, the most notable discrepancy with the recommendations was observed in iron intake (6.95 ± 2.87 mg/d vs 7.04 ± 2.98 mg/d, p > 0.05; RDA equal to 10 mg/d) primarily due to low consumption of meat products, and in calcium (406.96 mg/d vs 399.46 mg/d, p > 0.05; RDA of 1000 mg/d). Most of the children in this study had a FC of dairy products below the recommended consumption frequency. This study highlights the importance of improving dietary guidance for both groups studied, with particular attention to children with ASD to avoid any complications of ASD.

自闭症谱系障碍(ASD)会影响儿童的营养状况。本研究旨在评估自闭症谱系障碍儿童每日膳食中微量营养素的摄入量(DDI)以及不同食物类别的食用频率(FC),并将其与典型发育(TD)儿童进行比较。研究还将确定这些摄入量在多大程度上符合膳食营养素推荐摄入量(RDA)。这项研究包括 52 名儿童,其中 26 名患有 ASD,26 名患有 TD。通过7天的食物日记收集了DDI和FC。在微量营养素的DDI中,只有维生素B12在病例和对照组之间有显著差异,但在研究的两个组别中,DDI都高于推荐值。在我们的研究样本中,所有儿童的铁、钙、维生素 E 和 K1 的 DDI 都低于 RDA。然而,与推荐值差距最大的是铁的摄入量(6.95 ± 2.87 mg/d vs 7.04 ± 2.98 mg/d,p > 0.05;RDA 等于 10 mg/d)和钙的摄入量(406.96 mg/d vs 399.46 mg/d,p > 0.05;RDA 为 1000 mg/d)。在这项研究中,大多数儿童的奶制品消费频率低于建议消费频率。这项研究强调了改善对所研究的两组儿童的膳食指导的重要性,尤其要关注患有自闭症的儿童,以避免自闭症的并发症。
{"title":"L’apport alimentaire en micronutriments dans le trouble du spectre de l’autisme chez des enfants de l’ouest Algérien","authors":"Nawel Amraoui ,&nbsp;Nouria Dennouni-Medjati ,&nbsp;Majda Dali-Sahi ,&nbsp;Yahia Harek ,&nbsp;Baya Guermouche ,&nbsp;Cherifa Benosman","doi":"10.1016/j.nupar.2023.09.005","DOIUrl":"10.1016/j.nupar.2023.09.005","url":null,"abstract":"<div><p>Autism Spectrum Disorders (ASD) can affect the nutritional status of children. This study aimed to assess the daily dietary intakes (DDI) of micronutrients, as well as the frequency of consumption (FC) of different food groups, in children with ASD and compare them to those with typical development (TD). It will also determine to what extent these intakes comply with the Recommanded Dietary Allowances (RDA). The study included 52 children, 26 with ASD and 26 with TD. DDI and FC were gathered using a 7-day food diary. Among the DDI of micronutrient, only Vit B12 showed a significant difference between cases and controls, but the DDI was higher than the recommendations in both groups studied. All the children of our study sample had DDI lower than the RDA, in iron, calcium, vitamins E and K1. However, the most notable discrepancy with the recommendations was observed in iron intake (6.95<!--> <!-->±<!--> <!-->2.87<!--> <!-->mg/d vs 7.04<!--> <!-->±<!--> <!-->2.98<!--> <!-->mg/d, p<!--> <!-->&gt;<!--> <!-->0.05; RDA equal to 10<!--> <!-->mg/d) primarily due to low consumption of meat products, and in calcium (406.96<!--> <!-->mg/d vs 399.46<!--> <!-->mg/d, p<!--> <!-->&gt;<!--> <!-->0.05; RDA of 1000<!--> <!-->mg/d). Most of the children in this study had a FC of dairy products below the recommended consumption frequency. This study highlights the importance of improving dietary guidance for both groups studied, with particular attention to children with ASD to avoid any complications of ASD.</p></div>","PeriodicalId":54702,"journal":{"name":"Nutrition Clinique et Metabolisme","volume":"38 1","pages":"Pages 16-21"},"PeriodicalIF":0.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139395739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
L’éditorial de la présidente de la SFNCM 港区管委会主席的社论
IF 0.6 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-03-01 DOI: 10.1016/j.nupar.2024.02.001
Francisca Joly
{"title":"L’éditorial de la présidente de la SFNCM","authors":"Francisca Joly","doi":"10.1016/j.nupar.2024.02.001","DOIUrl":"https://doi.org/10.1016/j.nupar.2024.02.001","url":null,"abstract":"","PeriodicalId":54702,"journal":{"name":"Nutrition Clinique et Metabolisme","volume":"38 1","pages":"Page 1"},"PeriodicalIF":0.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139992670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High coffee consumption is not associated with less liver fibrosis in non-alcoholic steato-hepatitis: Results of the COCANASH study 大量饮用咖啡与非酒精性脂肪性肝炎患者肝纤维化程度降低无关:COCANASH 研究结果
IF 0.6 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-03-01 DOI: 10.1016/j.nupar.2023.10.001
Hugues Blondon , Marc Delord , Simona Cosconea , Simona Tirziu , Marie-Pierre Ripault , Florent Ehrhard , Matthieu Schnee , Khaldoun Elriz , Mathilde Fron , Kamel Benghalia , Margot Laly , Sylvie Roussin-Bretagne , Carelle Koudougou , Gwenaelle Petit-Aubert , Vincent Mace , Michel Chochon , Cécile Garceau , Philippe Colardelle , Ludovic Lagin , Mélody Fort , Cédric Villain

Background

The beneficial effect of coffee consumption on the progression of liver fibrosis in NASH is controversial.

Aims

To compare coffee consumption in NASH patients with and without advanced fibrosis.

Methods

Cross-sectional observational study on 97 patients with NASH diagnosed by histology or the association of steatosis, metabolic syndrome, elastometry > 6 kPa, and exclusion of other liver diseases. Usual coffee and caffeine intake were assessed using a standardized questionnaire. Liver fibrosis was evaluated by elastometry (advanced fibrosis if ≥ 10 kPa).

Results

Among the 97 patients, 49 patients (51%) had non-advanced fibrosis (group 1) and 48 (49%) advanced fibrosis (group 2). The mean consumption of caffeine from coffee was 251 mg ± 293 per day in group 1 and 257 mg ± 286 per day in group 2 (P = 0.92). In multivariable analysis, the odds ratio for the mean consumption of caffeine from coffee (100 mg/d) between groups was 1.00 (1.00–1.00, P = 0.92). There was no correlation between elastometry and the consumption of caffeine from coffee.

Conclusion

We found no relationship between caffeine or coffee consumption and the degree of liver fibrosis in NASH. Our result does not support a beneficial effect of coffee consumption on the progression of fibrosis in NASH.

背景饮用咖啡对NASH患者肝纤维化进展的有益影响尚存争议。方法对97名通过组织学或脂肪变性、代谢综合征、弹性测量> 6 kPa诊断的NASH患者进行横断面观察研究,并排除其他肝脏疾病。通过标准化问卷对患者平时的咖啡和咖啡因摄入量进行了评估。结果97名患者中,49人(51%)为非晚期肝纤维化(第1组),48人(49%)为晚期肝纤维化(第2组)。第1组患者每天从咖啡中摄入咖啡因的平均量为251毫克±293毫克,第2组患者每天从咖啡中摄入咖啡因的平均量为257毫克±286毫克(P=0.92)。在多变量分析中,组间咖啡咖啡因平均摄入量(100 毫克/天)的几率比为 1.00 (1.00-1.00, P = 0.92)。结论我们发现咖啡因或咖啡的摄入量与 NASH 患者肝纤维化程度之间没有关系。我们的研究结果不支持饮用咖啡对NASH肝纤维化进展的有益影响。
{"title":"High coffee consumption is not associated with less liver fibrosis in non-alcoholic steato-hepatitis: Results of the COCANASH study","authors":"Hugues Blondon ,&nbsp;Marc Delord ,&nbsp;Simona Cosconea ,&nbsp;Simona Tirziu ,&nbsp;Marie-Pierre Ripault ,&nbsp;Florent Ehrhard ,&nbsp;Matthieu Schnee ,&nbsp;Khaldoun Elriz ,&nbsp;Mathilde Fron ,&nbsp;Kamel Benghalia ,&nbsp;Margot Laly ,&nbsp;Sylvie Roussin-Bretagne ,&nbsp;Carelle Koudougou ,&nbsp;Gwenaelle Petit-Aubert ,&nbsp;Vincent Mace ,&nbsp;Michel Chochon ,&nbsp;Cécile Garceau ,&nbsp;Philippe Colardelle ,&nbsp;Ludovic Lagin ,&nbsp;Mélody Fort ,&nbsp;Cédric Villain","doi":"10.1016/j.nupar.2023.10.001","DOIUrl":"10.1016/j.nupar.2023.10.001","url":null,"abstract":"<div><h3>Background</h3><p>The beneficial effect of coffee consumption on the progression of liver fibrosis in NASH is controversial.</p></div><div><h3>Aims</h3><p>To compare coffee consumption in NASH patients with and without advanced fibrosis.</p></div><div><h3>Methods</h3><p>Cross-sectional observational study on 97 patients with NASH diagnosed by histology or the association of steatosis, metabolic syndrome, elastometry<!--> <!-->&gt;<!--> <!-->6<!--> <!-->kPa, and exclusion of other liver diseases. Usual coffee and caffeine intake were assessed using a standardized questionnaire. Liver fibrosis was evaluated by elastometry (advanced fibrosis if ≥<!--> <!-->10<!--> <!-->kPa).</p></div><div><h3>Results</h3><p>Among the 97 patients, 49 patients (51%) had non-advanced fibrosis (group 1) and 48 (49%) advanced fibrosis (group 2). The mean consumption of caffeine from coffee was 251<!--> <!-->mg<!--> <!-->±<!--> <!-->293 per day in group 1 and 257<!--> <!-->mg<!--> <!-->±<!--> <!-->286 per day in group 2 (<em>P</em> <!-->=<!--> <!-->0.92). In multivariable analysis, the odds ratio for the mean consumption of caffeine from coffee (100<!--> <!-->mg/d) between groups was 1.00 (1.00–1.00, <em>P</em> <!-->=<!--> <!-->0.92). There was no correlation between elastometry and the consumption of caffeine from coffee.</p></div><div><h3>Conclusion</h3><p>We found no relationship between caffeine or coffee consumption and the degree of liver fibrosis in NASH. Our result does not support a beneficial effect of coffee consumption on the progression of fibrosis in NASH.</p></div>","PeriodicalId":54702,"journal":{"name":"Nutrition Clinique et Metabolisme","volume":"38 1","pages":"Pages 22-26"},"PeriodicalIF":0.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139195812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human gut microbial ecology and association with postbiotics; prophylactic and diagnostic application 人类肠道微生物生态学及其与益生元后的关联;预防和诊断应用
IF 0.6 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-02-13 DOI: 10.1016/j.nupar.2023.12.003
K. Hemamalini , A.B. Chavhan , B. Babitha , J. Madhavi , M.K. Verma

The microbial ecology of the human gut is made up of many different species of beneficial microorganisms, mostly bacteria. The integrity of the gut and general health are crucially dependent on these beneficial bacterial species. A variety of microbial communities reside in the human gut in symbiotic interactions, the majority of which are advantageous. According to reports, aberrant bacterial species colonization causes gut dysbiosis and serves as a catalyst for a number of human diseases. Understanding the diverse microbial species that live in the human gut and how they are related to human health and a number of disorders has been the subject of extensive research. Less research has been done on the postbiotics, such as chemistry and biochemistry, and their connections to human health. Postbiotics are defined as non-viable microbial cells, metabolic metabolites, and their microbial by-products released after lysis. Understanding the postbiotic landscape is essential to determining its source and method of synthesis, whether natural or artificial. Therefore, it is crucial to profile the ecology of the gut's microbes as well as the habitat since these factors have an impact on the postbiotic metabolites that are created. In order to relate human health and disease based on postbiotic rather than microbial species, it will be more important to address specific metabolites. The present study stresses the importance of gut microbial ecology in human physiology and health. Postbiotics profiles may be helpful in gaining access to gut ecology, and these molecular markers may act as early diagnostic tools for a variety of disorders. The most recent studies show that postbiotics increase immunological function, allergic reactions, neurological diseases, acute and chronic diarrhoea, and immune function. In the future, effort can be made to develop a quantitative-effect relationship evaluation method that is more rational, scientific, and better to give stronger support for the healthy and long-term development of postbiotic preparations.

人体肠道的微生物生态由许多不同种类的有益微生物(主要是细菌)组成。肠道的完整性和整体健康在很大程度上取决于这些有益细菌的种类。人体肠道内存在多种微生物群落,它们之间存在共生互动关系,其中大多数都是有益的。据报道,异常细菌物种定植会导致肠道菌群失调,并成为多种人类疾病的催化剂。了解生活在人体肠道中的各种微生物物种,以及它们与人体健康和多种疾病的关系,一直是广泛研究的主题。关于后生 物(如化学和生物化学)及其与人类健康的关系的研究较少。后益生菌的定义是不能存活的微生物细胞、代谢代谢物及其裂解后释放的微生物副产物。要确定后生 物的来源和合成方法(无论是天然的还是人工的),就必须了解后生 物的情况。因此,对肠道微生物生态和栖息地进行剖析至关重要,因为这些因素会对产生的后生物代谢物产生影响。为了根据生物后代谢物而不是微生物种类将人类健康与疾病联系起来,更重要的是要研究特定的代谢物。本研究强调了肠道微生物生态对人体生理和健康的重要性。后生物素图谱可能有助于了解肠道生态,这些分子标记物可作为各种疾病的早期诊断工具。最新研究表明,益生菌后可增强免疫功能、过敏反应、神经系统疾病、急慢性腹泻和免疫功能。今后,可以努力开发一种更合理、更科学、更完善的量效关系评价方法,为益生元后制剂的健康、长远发展提供更有力的支持。
{"title":"Human gut microbial ecology and association with postbiotics; prophylactic and diagnostic application","authors":"K. Hemamalini ,&nbsp;A.B. Chavhan ,&nbsp;B. Babitha ,&nbsp;J. Madhavi ,&nbsp;M.K. Verma","doi":"10.1016/j.nupar.2023.12.003","DOIUrl":"10.1016/j.nupar.2023.12.003","url":null,"abstract":"<div><p>The microbial ecology of the human gut is made up of many different species of beneficial microorganisms, mostly bacteria. The integrity of the gut and general health are crucially dependent on these beneficial bacterial species. A variety of microbial communities reside in the human gut in symbiotic interactions, the majority of which are advantageous. According to reports, aberrant bacterial species colonization causes gut dysbiosis and serves as a catalyst for a number of human diseases. Understanding the diverse microbial species that live in the human gut and how they are related to human health and a number of disorders has been the subject of extensive research. Less research has been done on the postbiotics, such as chemistry and biochemistry, and their connections to human health. Postbiotics are defined as non-viable microbial cells, metabolic metabolites, and their microbial by-products released after lysis. Understanding the postbiotic landscape is essential to determining its source and method of synthesis, whether natural or artificial. Therefore, it is crucial to profile the ecology of the gut's microbes as well as the habitat since these factors have an impact on the postbiotic metabolites that are created. In order to relate human health and disease based on postbiotic rather than microbial species, it will be more important to address specific metabolites. The present study stresses the importance of gut microbial ecology in human physiology and health. Postbiotics profiles may be helpful in gaining access to gut ecology, and these molecular markers may act as early diagnostic tools for a variety of disorders. The most recent studies show that postbiotics increase immunological function, allergic reactions, neurological diseases, acute and chronic diarrhoea, and immune function. In the future, effort can be made to develop a quantitative-effect relationship evaluation method that is more rational, scientific, and better to give stronger support for the healthy and long-term development of postbiotic preparations.</p></div>","PeriodicalId":54702,"journal":{"name":"Nutrition Clinique et Metabolisme","volume":"38 2","pages":"Pages 71-81"},"PeriodicalIF":0.6,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139820754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Board
IF 0.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-12-01 DOI: 10.1016/S0985-0562(24)00002-5
{"title":"Board","authors":"","doi":"10.1016/S0985-0562(24)00002-5","DOIUrl":"10.1016/S0985-0562(24)00002-5","url":null,"abstract":"","PeriodicalId":54702,"journal":{"name":"Nutrition Clinique et Metabolisme","volume":"37 2","pages":"Page ii"},"PeriodicalIF":0.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143274534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Actualités de la pharmacothérapie de l’obésité en 2023
IF 0.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-12-01 DOI: 10.1016/S0985-0562(24)00015-3
Pierre Bel Lassen , Judith Aron-Wisnewsky
Significant progress have been made in the management of obesity thanks to the emergence of effective drug treatments, combined with dietary advice and regular physical activity. Unlike previous drugs tested, these new therapies allow for significant weight loss without serious side effects. They act primarily by increasing feelings of satiety and reducing food intake without frustration. GLP1 receptor agonists, such as liraglutide and semaglutide, are already recommended therapeutic options for the management of obesity in France. This review examines the mechanisms, efficacy, and side effects of the main drugs currently available on prescription.
© 2023 Société francophone nutrition clinique et métabolisme (SFNCM).
Published by Elsevier Masson SAS. All rights reserved.
{"title":"Actualités de la pharmacothérapie de l’obésité en 2023","authors":"Pierre Bel Lassen ,&nbsp;Judith Aron-Wisnewsky","doi":"10.1016/S0985-0562(24)00015-3","DOIUrl":"10.1016/S0985-0562(24)00015-3","url":null,"abstract":"<div><div>Significant progress have been made in the management of obesity thanks to the emergence of effective drug treatments, combined with dietary advice and regular physical activity. Unlike previous drugs tested, these new therapies allow for significant weight loss without serious side effects. They act primarily by increasing feelings of satiety and reducing food intake without frustration. GLP1 receptor agonists, such as liraglutide and semaglutide, are already recommended therapeutic options for the management of obesity in France. This review examines the mechanisms, efficacy, and side effects of the main drugs currently available on prescription.</div><div>© 2023 Société francophone nutrition clinique et métabolisme (SFNCM).</div><div>Published by Elsevier Masson SAS. All rights reserved.</div></div>","PeriodicalId":54702,"journal":{"name":"Nutrition Clinique et Metabolisme","volume":"37 2","pages":"Pages 2S70-2S73"},"PeriodicalIF":0.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143274552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Title Page
IF 0.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-12-01 DOI: 10.1016/S0985-0562(24)00001-3
{"title":"Title Page","authors":"","doi":"10.1016/S0985-0562(24)00001-3","DOIUrl":"10.1016/S0985-0562(24)00001-3","url":null,"abstract":"","PeriodicalId":54702,"journal":{"name":"Nutrition Clinique et Metabolisme","volume":"37 2","pages":"Page i"},"PeriodicalIF":0.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143274533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rôle de l’axe microbiote-intestin-cerveau dans la dérégulation du comportement alimentaire au cours de l’obésité et de l’hyperphagie boulimique : les mécanismes
IF 0.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-12-01 DOI: 10.1016/S0985-0562(24)00007-4
Marie Galmiche , Pierre Déchelotte
Eating disorders (ED), particularly compulsive ED such as binge eating disorder (BED), play an important role in the pathophysiology of obesity. Recent data have highlighted the involvement of the microbiotagut-brain axis in the regulation of eating behavior; its deregulation could therefore contribute to the onset of obesity via the development or perpetuation of ED, in particular BED. This review highlights the various peripheral and central pathophysiological mechanisms linking intestinal dysbiosis and the disruption of eating behavior leading to obesity and BED. The main peripheral regulatory signals involved are peptides associated with food intake (ghrelin, GLP-1), short-chain fatty acids and bacterial components. The brain integration of peripheral and central signals modulating food intake, involving at homeostatic (arcuate nucleus of the hypothalamus) and hedonic (reward system) levels, will be described during BED and obesity. This better understanding of the role of the microbiota-gut-brain axis in the control of eating behavior in relation to the pathophysiology of obesity opens up prospects for innovative therapeutic strategies targeting gut microbiota reshaping.
© 2023 Société francophone nutrition clinique et métabolisme (SFNCM).
Published by Elsevier Masson SAS. All rights reserved.
{"title":"Rôle de l’axe microbiote-intestin-cerveau dans la dérégulation du comportement alimentaire au cours de l’obésité et de l’hyperphagie boulimique : les mécanismes","authors":"Marie Galmiche ,&nbsp;Pierre Déchelotte","doi":"10.1016/S0985-0562(24)00007-4","DOIUrl":"10.1016/S0985-0562(24)00007-4","url":null,"abstract":"<div><div>Eating disorders (ED), particularly compulsive ED such as binge eating disorder (BED), play an important role in the pathophysiology of obesity. Recent data have highlighted the involvement of the microbiotagut-brain axis in the regulation of eating behavior; its deregulation could therefore contribute to the onset of obesity via the development or perpetuation of ED, in particular BED. This review highlights the various peripheral and central pathophysiological mechanisms linking intestinal dysbiosis and the disruption of eating behavior leading to obesity and BED. The main peripheral regulatory signals involved are peptides associated with food intake (ghrelin, GLP-1), short-chain fatty acids and bacterial components. The brain integration of peripheral and central signals modulating food intake, involving at homeostatic (arcuate nucleus of the hypothalamus) and hedonic (reward system) levels, will be described during BED and obesity. This better understanding of the role of the microbiota-gut-brain axis in the control of eating behavior in relation to the pathophysiology of obesity opens up prospects for innovative therapeutic strategies targeting gut microbiota reshaping.</div><div>© 2023 Société francophone nutrition clinique et métabolisme (SFNCM).</div><div>Published by Elsevier Masson SAS. All rights reserved.</div></div>","PeriodicalId":54702,"journal":{"name":"Nutrition Clinique et Metabolisme","volume":"37 2","pages":"Pages 2S16-2S25"},"PeriodicalIF":0.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143274539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Faire face à l’obésité : progrès dans la physiopathologie et la prise en charge médicale
IF 0.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-12-01 DOI: 10.1016/S0985-0562(24)00004-9
Marie-Claude Brindisi , Pierre Déchelotte
{"title":"Faire face à l’obésité : progrès dans la physiopathologie et la prise en charge médicale","authors":"Marie-Claude Brindisi ,&nbsp;Pierre Déchelotte","doi":"10.1016/S0985-0562(24)00004-9","DOIUrl":"10.1016/S0985-0562(24)00004-9","url":null,"abstract":"","PeriodicalId":54702,"journal":{"name":"Nutrition Clinique et Metabolisme","volume":"37 2","pages":"Page 2S1"},"PeriodicalIF":0.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143274537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surpoids et obésité de l’enfant et l’adolescent : quel parcours de soins en 2023 ?
IF 0.5 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Pub Date : 2023-12-01 DOI: 10.1016/S0985-0562(24)00011-6
Béatrice Dubern
In link with the interministerial plan for obesity (2019-2022), the French National Authority for Health (HAS) has published in 2022 a guide to optimize the care pathway for overweight and obese children and adolescents to support healthcare professionals in its implementation. The guide particularly emphases on the importance of calculating Body Mass Index (BMI) throughout childhood, at every opportunity, to optimize screening for overweight and obesity. In case where excess weight has been established, it details the importance of multidisciplinary assessment of each situation, with considering several important aspects (socio-cultural, psycho-affective, etc.) and detailing the levers that professionals can use throughout this care pathway that must be coordinated and graduated on the long-term manner if it is to be effective.
© 2023 Société francophone nutrition clinique et métabolisme (SFNCM).
Published by Elsevier Masson SAS. All rights reserved.
{"title":"Surpoids et obésité de l’enfant et l’adolescent : quel parcours de soins en 2023 ?","authors":"Béatrice Dubern","doi":"10.1016/S0985-0562(24)00011-6","DOIUrl":"10.1016/S0985-0562(24)00011-6","url":null,"abstract":"<div><div>In link with the interministerial plan for obesity (2019-2022), the French National Authority for Health (HAS) has published in 2022 a guide to optimize the care pathway for overweight and obese children and adolescents to support healthcare professionals in its implementation. The guide particularly emphases on the importance of calculating Body Mass Index (BMI) throughout childhood, at every opportunity, to optimize screening for overweight and obesity. In case where excess weight has been established, it details the importance of multidisciplinary assessment of each situation, with considering several important aspects (socio-cultural, psycho-affective, etc.) and detailing the levers that professionals can use throughout this care pathway that must be coordinated and graduated on the long-term manner if it is to be effective.</div><div>© 2023 Société francophone nutrition clinique et métabolisme (SFNCM).</div><div>Published by Elsevier Masson SAS. All rights reserved.</div></div>","PeriodicalId":54702,"journal":{"name":"Nutrition Clinique et Metabolisme","volume":"37 2","pages":"Pages 2S46-2S51"},"PeriodicalIF":0.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143274555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nutrition Clinique et Metabolisme
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1